| DC Field | Value | Language |
|---|
| dc.contributor.author | Korsakov, M. K. | - |
| dc.contributor.author | Fedorov, V. N. | - |
| dc.contributor.author | Smirnov, N. A. | - |
| dc.contributor.author | Shetnev, A. A. | - |
| dc.contributor.author | Leonova, O. V. | - |
| dc.date.accessioned | 2024-05-06T12:02:36Z | - |
| dc.date.available | 2024-05-06T12:02:36Z | - |
| dc.date.issued | 2023 | - |
| dc.identifier.citation | Screening of anti-inflammatory activity of 4.5- dihydroisoxazol-5-carboxamide (PAR-2 inhibitors) based on formaldehyde oedema model among white lab rats / M.K. Korsakov, V.N. Fedorov, N.A. Smirnov [et al.] // Research Results in Pharmacology. - 2023. - Vol.9, №4.-P. 105-111. | ru |
| dc.identifier.uri | http://dspace.bsu.edu.ru/handle/123456789/62690 | - |
| dc.description.abstract | Rheumatoid arthritis (RА) is an immune-inflammatory disease intrinsic to up to 1.0% of the world’s population. Standard drugs for RA therapy are basic medications, glucocorticoids and non-steroid anti-inflammatory drugs, which often only ease or hinder the course of disease, not curing the patient completely | ru |
| dc.language.iso | en | ru |
| dc.subject | medicine | ru |
| dc.subject | pharmacology | ru |
| dc.subject | 4.5-dihydroisoxazol-5-carboxamide derivatives | ru |
| dc.subject | formaldehyde oedema | ru |
| dc.subject | PAR-2 inhibitors | ru |
| dc.subject | rheumatoid arthritis | ru |
| dc.title | Screening of anti-inflammatory activity of 4.5- dihydroisoxazol-5-carboxamide (PAR-2 inhibitors) based on formaldehyde oedema model among white lab rats | ru |
| dc.type | Article | ru |
| Appears in Collections: | Vol. 9, № 4
|
